Sandoz Just Went Shopping in Shanghai. Here's What It Bought.
Sandoz just signed a $322 million biosimilar licensing deal with Shanghai Henlius, pushing its pipeline to 39 assets. It's the latest sign that the Swiss giant is building a biosimilar empire, and China is its favorite supplier.
The global biosimilar race just got a new power couple.
Sandoz, the Swiss company that's been on a tear since splitting from Novartis, signed a licensing deal with Shanghai Henlius Biotech worth up to $322 million. The prize: three biosimilar drugs, an option on a fourth asset, and a shot at dominating the next wave of patent cliffs.
This isn't a one-off shopping trip. It's part of a pattern that's reshaping how Western pharma fills its pipeline, and China is increasingly the store.
What's Actually in the Bag
Sandoz picked up global commercialization rights outside China for three biosimilars from Henlius:
HLX05-N, a proposed copycat of Erbitux (cetuximab), a cancer drug
HLX16, a proposed copycat of Repatha (evolocumab), a cholesterol drug
A proposed copycat of Benlysta (belimumab), a lupus drug
For anyone unfamiliar, biosimilars are essentially the generic version of biologic drugs. But "generic" undersells the complexity. Biologics are made from living cells, so copying them is more like trying to replicate a soufflé from someone else's kitchen than photocopying a recipe. They're hard to make, expensive to develop, and incredibly lucrative once approved.
Sandoz also grabbed an option on a recombinant human hyaluronidase (a protein that helps deliver drugs under the skin instead of through an IV). Think of it as the delivery truck that makes the medicine easier to take.
Henlius handles development and manufacturing. Sandoz handles selling the finished product across the U.S., Europe, Japan, Australia, and beyond. It's a clean division of labor: one side builds, the other sells.
Follow the Money
The deal's total value runs up to $322 million, but that number is a ceiling, not a check. It's structured as a milestones-based agreement, meaning Henlius gets paid as each drug clears specific development and commercial hurdles.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The breakdown, per Reuters: up to $77 million upfront, with development milestones reaching up to $160 million and commercial milestones adding another $77 million. Near-term payments tied to the initial three assets could hit $100.5 million.
For a deal covering three (potentially four) assets with global rights, that's a pretty reasonable price tag. Sandoz isn't overpaying for speculative science; it's buying late-stage biosimilar programs from a company that already has 10 product approvals across more than 60 countries.
Why Sandoz Can't Stop Buying
To understand why Sandoz keeps signing these deals, you need to understand what the company is. After spinning off from Novartis, Sandoz became the world's largest pure-play generics and biosimilars company. Its entire strategy is built on one bet: that the biosimilar market is about to explode.
And the math supports that bet. A massive wave of biologic drugs is losing patent protection over the next several years. We're talking about blockbusters that collectively generate tens of billions in annual sales. Every one of those expiring patents is a door that biosimilar makers want to kick open.
Sandoz has been stacking its pipeline accordingly. In March 2026, it signed a partnership with Samsung Bioepis covering up to five biosimilar assets, which pushed its total pipeline to roughly 32 assets. Now, with the Henlius deal, the company says its biosimilar pipeline has expanded to 39 assets, with the potential to reach 46.
Biosimilars already account for about 30% of Sandoz's total net sales as of fiscal year 2025, up from 28% in fiscal year 2024. That share is only going in one direction.
The company even created a dedicated global biosimilars unit under executive Armin Metzger to align development, manufacturing, and supply specifically for biosimilar market dynamics. When you reorganize your entire org chart around a business line, you're not dabbling; you're going all in.
The China Connection
This deal also highlights a bigger trend: Western pharma is increasingly looking east for pipeline replenishment.
Cross-border licensing from China hit record levels in 2025, with one estimate pegging total deal value at $137.7 billion. Analysts expect 2026 to break that record. Average upfront payments for Western–China licensing deals have grown significantly, jumping from $52 million in 2022, and 2026 is already running at a strong pace.
Most of the headline-grabbing China deals have involved innovative biologics (think novel cancer drugs, bispecific antibodies, and antibody-drug conjugates). Biosimilar licensing from China is a narrower slice of the pie, but Henlius is proof that it's a real and growing part of the story.
Henlius is no startup, either. Founded in 2010, the Shanghai-based company achieved China's first biosimilar approval and has since racked up FDA approvals, European Commission approvals, and partnerships stretching from Cipla to Accord Healthcare. In 2024, the company posted revenue of roughly RMB 5.7 billion (about $790 million) with a net profit of RMB 820.5 million. This is a profitable, scaled biosimilar manufacturer with global regulatory credentials.
What the Street Thinks
Wall Street liked what it saw. Sandoz shares rose more than 2% after the announcement.
Jefferies, which covers the stock, said it expects more in-licensing activity from Sandoz to fill what it called an "upcoming industry pipeline void." The firm valued the deal favorably within its price target framework.
The broader competitive implications are worth watching, too. Rivals like Teva, Celltrion, Biocon, Fresenius Kabi, and Alvotech are all fighting for position ahead of the same patent cliff. Sandoz's aggressive deal-making raises the stakes for everyone. If you're a mid-tier biosimilar player without a strong pipeline, you're now competing against a company with nearly 40 assets and a global distribution machine.
The Bigger Picture
Zoom out, and the Sandoz-Henlius deal tells a story about where the biosimilar industry is headed. The winners won't necessarily be the companies that develop every drug in-house. They'll be the ones who assemble the best portfolios, lock down manufacturing partnerships, and get to market fastest.
Sandoz is playing that game better than almost anyone right now. It's using China's deep bench of biologic developers as a pipeline engine, while keeping its own commercial infrastructure focused on what it does best: selling drugs at scale across major markets.
The biosimilar patent cliff is coming. Sandoz is building its army. And with 39 (and counting) assets in the pipeline, it's making sure it's the first one through the door when those patents fall.
Funding & Financings
5 min read
CSL Just Had Its Best Day in 25 Years. Here's What Lit the Fuse.
CSL posted a $2.6 billion net loss and its stock soared 18%, the best single-day move in 25 years. Behind the apparent contradiction lies a "reset year" ending, a massive buyback, and a plasma market where demand keeps outrunning supply.
